Zentalis Pharmaceuticals Llc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $24.355
- Today's High:
- $25.02
- Open Price:
- $24.85
- 52W Low:
- $15.55
- 52W High:
- $31.46
- Prev. Close:
- $24.95
- Volume:
- 657118
Company Statistics
- Market Cap.:
- $1.92 billion
- Book Value:
- 7.41
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -23.57%
- Return on Equity TTM:
- -57.29%
Company Profile
Zentalis Pharmaceuticals Llc had its IPO on 2020-04-03 under the ticker symbol ZNTL.
The company operates in the Healthcare sector and Biotechnology industry. Zentalis Pharmaceuticals Llc has a staff strength of 156 employees.
Stock update
Shares of Zentalis Pharmaceuticals Llc opened at $24.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $24.36 - $25.02, and closed at $24.7.
This is a -1% slip from the previous day's closing price.
A total volume of 657,118 shares were traded at the close of the day’s session.
In the last one week, shares of Zentalis Pharmaceuticals Llc have slipped by -8.99%.
Zentalis Pharmaceuticals Llc's Key Ratios
Zentalis Pharmaceuticals Llc has a market cap of $1.92 billion, indicating a price to book ratio of 2.661 and a price to sales ratio of 0.
In the last 12-months Zentalis Pharmaceuticals Llc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-222856992. The EBITDA ratio measures Zentalis Pharmaceuticals Llc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zentalis Pharmaceuticals Llc’s operating margin was 0% while its return on assets stood at -23.57% with a return of equity of -57.29%.
In Q2, Zentalis Pharmaceuticals Llc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Zentalis Pharmaceuticals Llc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.87 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zentalis Pharmaceuticals Llc’s profitability.
Zentalis Pharmaceuticals Llc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.24. Its price to sales ratio in the trailing 12-months stood at 0.
Zentalis Pharmaceuticals Llc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $621.44 million
- Total Liabilities
- $51.76 million
- Operating Cash Flow
- $72.93 million
- Capital Expenditure
- $319000
- Dividend Payout Ratio
- 0%
Zentalis Pharmaceuticals Llc ended 2024 with $621.44 million in total assets and $0 in total liabilities. Its intangible assets were valued at $621.44 million while shareholder equity stood at $523.14 million.
Zentalis Pharmaceuticals Llc ended 2024 with $0 in deferred long-term liabilities, $51.76 million in other current liabilities, 70000.00 in common stock, $-772111000.00 in retained earnings and $3.74 million in goodwill. Its cash balance stood at $266.56 million and cash and short-term investments were $552.99 million. The company’s total short-term debt was $2,335,000 while long-term debt stood at $0.
Zentalis Pharmaceuticals Llc’s total current assets stands at $563.93 million while long-term investments were $0.00 and short-term investments were $286.43 million. Its net receivables were $1.79 million compared to accounts payable of $12.31 million and inventory worth $8.22 million.
In 2024, Zentalis Pharmaceuticals Llc's operating cash flow was $72.93 million while its capital expenditure stood at $319000.
Comparatively, Zentalis Pharmaceuticals Llc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $24.7
- 52-Week High
- $31.46
- 52-Week Low
- $15.55
- Analyst Target Price
- $50.3
Zentalis Pharmaceuticals Llc stock is currently trading at $24.7 per share. It touched a 52-week high of $31.46 and a 52-week low of $31.46. Analysts tracking the stock have a 12-month average target price of $50.3.
Its 50-day moving average was $26.32 and 200-day moving average was $22.87 The short ratio stood at 28.25 indicating a short percent outstanding of 0%.
Around 273.4% of the company’s stock are held by insiders while 10208.7% are held by institutions.
Frequently Asked Questions About Zentalis Pharmaceuticals Llc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company’s products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.